Sigilon Therapeutics, Inc.
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
About us
The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Our Purpose
Serious chronic diseases today are often treated with chronic therapies. For patients with diseases such as lysosomal diseases or type 1 diabetes, they often are treated with frequent injections or infusions — sometimes multiple times daily — and constant, lifelong vigilance to manage their disease.
We developed our Shielded Living Therapeutics™ platform to address these treatment challenges. Leveraging advances in cell engineering and our proprietary biocompatible materials, we created a pipeline of potential therapies capable of producing proteins, enzymes and other therapeutic molecules that may be missing or deficient in the body—potentially resulting in functional cures for patients with a wide range of chronic diseases.